Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated ...
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 ...
bovnews4d
Why Did Tempest Therapeutics Inc (TPST) Stock Rise 11.03% to $1.51?
Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...
BioMarin Pharmaceutical (BMRN) Gets a Hold from Scotiabank
In a report released today, George Farmer from Scotiabank maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), ...